EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 451 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer April 26, 2024 Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 Satisfying Snacks November 13, 2020 Load more HOT NEWS FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... Experimental Drug Prevents Doxorubicin from Harming the Heart Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary...
